Key result
Atorvastatin improved flow-mediated dilation in subjects at risk for type 2 diabetes and decreased markers of endothelial activation and inflammation.
Why the study?
Does atorvastatin improve endothelial function in patients with diabetes and subjects at risk for type 2 diabetes?
RCT
Double-blind
randomized
Does atorvastatin improve endothelial function in patients with diabetes and subjects at risk for type 2 diabetes?
Atorvastatin improves endothelial function and reduces markers of inflammation and endothelial activation in patients with or at risk for type 2 diabetes.
Answers are grounded in this paper and cite their sources.
Supports atorvastatin for endothelial benefits in prediabetes; extends evidence of anti-inflammatory effects to diabetes risk groups.
We have investigated the effect of atorvastatin on the endothelial function of patients with diabetes and subjects at risk for type 2 diabetes in a 12-wk, prospective, randomized, placebo-controlled, double-blind clinical trial. The flow- mediated dilation (FMD; endothelium dependent) and nitroglycerin-induced dilation (endothelium independent) in the brachial artery and the vascular reactivity at the forearm skin were measured. FMD improved in the atorvastatin-treated, at-risk subjects [median (25-75 percentile), 7.2% (2.9-9.6%) at exit visit vs. 6.6% (2.9-9.5%) at baseline; P < 0.05]. A similar improvement of FMD was found in atorvastatin-treated diabetic patients [median (25-75 percentile), 5.6 (3.9-7.9) at exit visit vs. 4.2 (3.2-7.2) at baseline; P = 0.07]. No changes were observed in nitroglycerin-induced dilation and the microcirculation reactivity measurements in either group. In the at-risk group, there was a decrease in the C-reactive protein [median (25-75 percentile), 0.12 mg/dl (0.07-0.27 mg/dl) at exit visit vs. 0.24 mg/dl (0.07-0.35 mg/dl) at baseline; P < 0.05] and TNF alpha [median (25-75 percentile), 2.6 pg/ml (1.8-4.1 pg/ml) at exit visit vs. 4.4 pg/ml (3.6-6.0 pg/ml) at baseline; P < 0.05] in the atorvastatin-treated patients, whereas in the diabetes group, a decrease in endothelin-1 (mean +/- SD, 0.97 +/- 0.29 pg/ml at exit visit vs. 1.19 +/- 0.42 pg/ml at baseline; P < 0.05) and plasminogen activator inhibitor-1 [median (25-75 percentile), 18 ng/ml (9-24 ng/ml) at exit visit vs. 27 ng/ml (7-41 ng/ml) at baseline; P < 0.05] were observed. We conclude that atorvastatin improves endothelial function and decreases levels of markers of endothelial activation and inflammation.
No takes yet. Share an insight, caveat, or question.
Economides et al. (2004) conducted an RCT in Diabetes and at risk for type 2 diabetes. Atorvastatin vs. Placebo was evaluated on Flow-mediated dilation (FMD) (p=<0.05). Atorvastatin improved flow-mediated dilation in subjects at risk for type 2 diabetes and decreased markers of endothelial activation and inflammation.
Synapse has enriched 10 related papers. Consider them for comparative context: